Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Age \[7-13\] years for girls and \[7-14\] years for boys~  * With a T1D diagnosis (as ADA)~ * Treated with insulin for ≤ 3 months,~ * With at least one auto-antibody among: anti-insulin, anti-GAD, anti-IA2, anti-ZnT8 ;~* No clinically relevant abnormal findings for haematology, biochemistry, liver and kidney functions~* Informed consent signed by the patient, the parents, and the investigator before any intervention necessary for the trial.~Exclusion criteria :~* Contra-indications to IL-2 :~  * Hyper sensibility to IL-2 or its excipients,~ * Severe cardiopathy~ * Previous organ allograft~ * Ongoing infection requiring antibiotherapy,~ * O2 Saturation ≤ 90 %~ * Severe impairment of any vital organ~ * Documented history of other auto-immune diseases (except for auto-antibodies for, IAA, GADA, IA-2A, anti-ZnT8A, and stable thyroiditis with normal TSH (\<10 mUI/L), T3 and, T4 levels.~ * Diabetes onset characteristics including:~    * Continuous nocturnal polyuria ≥ 3 months ;~   * Inaugural acidosis (with venous Ph \< 7.25) ;~   * HbA1c at diagnostic ≥ 13%;~   * Weight loss ≥ 10 % at diagnosis ;~   * Positive autoantibodies to 21-hydroxylase~   * Stage 2 obesity~* Non authorized concomitant treatment : immuno-modulators, cytotoxic drugs, drug modifying plasma glycemia~* vaccination ≤ 4 weeks with life vaccin~* Positive serology (IgM) to the Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), reflecting an acute infection.~* Participation to another clinical investigation in previous 3 months~* No affiliation to National Health Insurance

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- interleukin-2 (Type: EXPERIMENTAL): Dose D1 of interleukin-2
- Dose D2 of interleukin-2 (Type: EXPERIMENTAL): Dose D2 of interleukin-2
- Dose D3 of interleukin-2 (Type: EXPERIMENTAL): Dose D3 of interleukin-2
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).